AN2 Therapeutics, Inc. (ANTX) Analyst Estimates Annual - Discounting Cash Flows
AN2 Therapeutics, Inc.
ANTX (NASDAQ)
Period Ending: 2028
12-31
2027
12-31
2026
12-31
2025
12-31
2024
12-31
2023
12-31
Number of Analysts 1 1 2 2 0 0
Estimated Revenue
Low 389.9 217 72.7 33.2 0 0
Average 389.9 217 72.7 33.2 0 0
High 389.9 217 72.7 33.2 0 0
Estimated EBITDA
Low 0 0 0 0 0 0
Average 0 0 0 0 0 0
High 0 0 0 0 0 0
Estimated EBIT
Low 0 0 0 0 0 0
Average 0 0 0 0 0 0
High 0 0 0 0 0 0
Estimated Net Income
Low -30.42 -29.53 -39.97 -39.55 -51.73 -72.6
Average -30.42 -29.53 -39.97 -36.99 -51.27 -70.71
High -30.42 -29.53 -39.97 -31.86 -50.82 -68.82
Estimated SGA Expenses
Low 0 0 0 0 0 0
Average 0 0 0 0 0 0
High 0 0 0 0 0 0
Estimated EPS
Low -1.02 -0.99 -1.34 -1.33 -1.73 -3.08
Average -1.02 -0.99 -1.34 -1.24 -1.72 -2.98
High -1.02 -0.99 -1.34 -1.07 -1.7 -2.92
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us